Survival Analysis Of TACE Combined With HIFU In The Treatment Of Liver Cancer

Background: HIFU(high intensity focused ultrasound)is a new technique of local ablation.Compared with other ablation methods,it is the only non-invasive treatment method at present and has received extensive attention.It is also more and more widely used in the treatment of liver cancer.Whether the combination of HIFU with the traditional non-surgical treatment TACE(transcatheter arterial chemoemboliza)is superior to TACE alone in the treatment of liver cancer has no definite conclusion.A large number of experimental studies are needed to explore the efficacy of TACE combined with HIFU in the treatment of liver cancer.Objective: To investigate the therapeutic effects of TACE combined with HIFU and the sole TACE in treating primary carcinoma of liver.Methods: With the method of retrospective analysis,121 patients suffering from primary carcinoma of liver were selected from the Second Affiliated Hospital of Chongqing Medical University from January 2015 toAugust 2016.They were divided into two groups which were the TACE combined HIFU group(experimental group)with 55 patients and the sole TACE group(control group)with 66 patients.The postoperative clinical effects,postperative adverse reactions,the survival rate of one year and the progression free survival time were compared between these two groups.Results: The propensity score matching method was used to balance the covariates between the two groups,and the imbalance of levels of AFP and whether within portal venous tumor emboli between two groups were balanced after matching.After matching,the 1-year survival rate of HIFU group was 94.0%,which was higher than 75.0% that of group TACE,and the difference was statistically significant(P<0.05).There were no differences between the two groups on the progression free survival(P>0.05).Conclution: Compared with solo TACE,the treatment of TACE combined with HIFU can prolong the 1-year survival rate of patients with primary liver cancer.